Wednesday, September 24th, 2003 - Eli Lilly and Company: Fewer Side Effects Reduce Costly Supportive Care for Non-Small Cell Lung Cancer Patients; Survival Rate with Alimta(R) (pemetrexed) Similar to Taxotere(R) (docetaxel), But Investigational Drug’s Side Effects Significantly Fewer
